RxDoctor Payments Data

Justiniano Castro Montalvo, MD

Hematology & Oncology · Arecibo, PRNPI 1811041114

Payments from drug & device makers

$3,420in general payments, 2019–2025

Across 40 payments — averaging $85.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • Bristol Myers Squibb$124
  • Genentech USA, Inc.$115
  • PBG Puerto Rico LLC$64
  • Karyopharm Therapeutics Inc.$47
  • Sanofi$46
  • plus $287 from 11 others

What the payments were for

  • Consulting fees$2,38070%
  • Travel & lodging$120%
  • Food & beverage$84425%
  • Education$1845%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,420 in reported general payments places this provider in the 25th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$19,488
Medicare patients
17
Services billed
2,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide61$936,577
VerzenioAbemaciclib33$482,034
SprycelDasatinib37$396,152
XtandiEnzalutamide21$283,104
ImbruvicaIbrutinib17$272,876
NerlynxNeratinib Maleate12$220,270
BesremiRopeginterferon Alfa-2b-Njft13$219,347
LonsurfTrifluridine/Tipiracil Hcl12$173,620
JakafiRuxolitinib Phosphate12$102,649
CalquenceAcalabrutinib Maleate12$91,469
ThalomidThalidomide12$58,064
ZarxioFilgrastim-Sndz17$46,451
Everolimus20$33,912
EliquisApixaban16$9,786
RetacritEpoetin Alfa-Epbx16$7,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid, Thalomid$124$994,64173 claims
E.r. Squibb & Sons, L.L.C.Sprycel$23$396,15237 claims
Astellas Pharma US IncXtandi$22$283,10421 claims
Pharmaessentia USA CorporationBesremi$23$219,34713 claims
AbbVieSynthroid$21$1,28226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Arecibo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →